| Project/Area Number |
15K09744
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
IWATSUKI Keiji 岡山大学, 医歯薬学総合研究科, 教授 (80126797)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
三宅 智子 岡山大学, 大学病院, 助教 (30749627)
平井 陽至 岡山大学, 大学病院, 助教 (10756068)
濱田 利久 岡山大学, 大学病院, 講師 (70346435)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | ＥＢウイルス / T/NKリンパ異常増殖症 / 種痘様水疱症 / 蚊刺過敏症 / 慢性活動性EBV感染症 / ウイルス関連リンパ腫 / 予後因子 / Ｔ／ＮＫリンパ異常増殖症 / 臨床 / ウイルス / 感染症 / 癌 / 細胞・組織 |
|---|
| Outline of Final Research Achievements |
Cutaneous EBV-associated T/NK lymphoproliferative disorders (LPDs) include hydroa vacciniforme (HV) and hypersensitivity to mosquito bites (HMB). We have proposed a clinical spectrum of EBV-associated T/NK LPDs including HV and HMB, and launched guidelines for managements of these disorders. Patients with HV are divided into two groups: a benign subtype designated classic HV (cHV), and more serious systemic HV (sHV). Patients with cHV have increased numbers of EBV-infected gdT cells, and show a favorable prognosis. Patients with sHV are further classified into two groups: gdT-cell- and abT-cell-dominant types. Patients with HMB, with or without HV-like eruptions, have increased numbers of EBV-infected NK cells in the blood. Patients with abT-cell-dominant sHV and HMB have a poor prognosis. In addition to our clinical subtypes and the responsible lymphocyte subsets, the poor prognostic indicators include onset age over 9 years, and the expression of the reactivation marker, BZLF1 mRNA.
|
